The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies
Objective: to assess the compliance of the actual practice of conducting clinical and economic research with the requirements applicable in the Russian Federation (RF) when including drugs in the Federal Program of High-Cost Nosologies (HCN).Material and methods. In the CyberLeninka and eLibrary databases, a search was made for clinical and economic studies of medicines included in the HCN list published in the RF in the period from 2011 to June 2021.Results. Information was obtained on 23 published clinical and economic studies of the effectiveness of drugs, which is less than 30% of all drugs included in the HCN program during the specified period. More than half of the studies of chronic disabling diseases had a modeling horizon of 1 year. The sensitivity analysis of the results in over 1/3 of cases considered only the deviation of the price of the strategies under consideration, and in a quarter of cases it was not carried out at all. Only 4 studies evaluated the increase in quality-adjusted life year, although, for chronic disabling diseases, quality of life is one of the key performance indicators.Conclusion. In the RF, less than 30% of the results of pharmacoeconomical studies of drugs included in the HCN Program are published, which does not allow to make adequate evaluation of pharmacoeconomical approaches to its formation. To analyze the effectiveness of the tools used in assessing the economic efficiency of expensive medical technologies, a further retrospective research of the studies conducted in the RF is required..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Фармакоэкономика - 15(2022), 1, Seite 87-105 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
A. S. Kolbin [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Biomedical cell products |
|---|
| doi: |
10.17749/2070-4909/farmakoekonomika.2022.107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ027579522 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ027579522 | ||
| 003 | DE-627 | ||
| 005 | 20230410103218.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17749/2070-4909/farmakoekonomika.2022.107 |2 doi | |
| 035 | |a (DE-627)DOAJ027579522 | ||
| 035 | |a (DE-599)DOAJ411137fa18374be49b88cd7009aea2a7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RM1-950 | |
| 050 | 0 | |a HB71-74 | |
| 100 | 0 | |a A. S. Kolbin |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective: to assess the compliance of the actual practice of conducting clinical and economic research with the requirements applicable in the Russian Federation (RF) when including drugs in the Federal Program of High-Cost Nosologies (HCN).Material and methods. In the CyberLeninka and eLibrary databases, a search was made for clinical and economic studies of medicines included in the HCN list published in the RF in the period from 2011 to June 2021.Results. Information was obtained on 23 published clinical and economic studies of the effectiveness of drugs, which is less than 30% of all drugs included in the HCN program during the specified period. More than half of the studies of chronic disabling diseases had a modeling horizon of 1 year. The sensitivity analysis of the results in over 1/3 of cases considered only the deviation of the price of the strategies under consideration, and in a quarter of cases it was not carried out at all. Only 4 studies evaluated the increase in quality-adjusted life year, although, for chronic disabling diseases, quality of life is one of the key performance indicators.Conclusion. In the RF, less than 30% of the results of pharmacoeconomical studies of drugs included in the HCN Program are published, which does not allow to make adequate evaluation of pharmacoeconomical approaches to its formation. To analyze the effectiveness of the tools used in assessing the economic efficiency of expensive medical technologies, a further retrospective research of the studies conducted in the RF is required. | ||
| 650 | 4 | |a high-cost nosologies | |
| 650 | 4 | |a innovative medicines | |
| 650 | 4 | |a biomedical cell products | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 653 | 0 | |a Economics as a science | |
| 700 | 0 | |a Yu. M. Gomon |e verfasserin |4 aut | |
| 700 | 0 | |a A. R. Kasimova |e verfasserin |4 aut | |
| 700 | 0 | |a A. A. Kurylev |e verfasserin |4 aut | |
| 700 | 0 | |a A. E. Bem |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Фармакоэкономика |d IRBIS LLC, 2019 |g 15(2022), 1, Seite 87-105 |w (DE-627)DOAJ000119067 |x 20704933 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:1 |g pages:87-105 |
| 856 | 4 | 0 | |u https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.107 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/411137fa18374be49b88cd7009aea2a7 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.pharmacoeconomics.ru/jour/article/view/661 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2070-4909 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2070-4933 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 1 |h 87-105 | ||